Your browser doesn't support javascript.
loading
Octreotide treatment in patients with necrotizing pancreatitis and pulmonary failure.
Fiedler, F; Jauernig, G; Keim, V; Richter, A; Bender, H J.
Afiliação
  • Fiedler F; Institut für Anästhesiologie und Intensivmedizin, Klinikum Mannheim, Fakultät für Klinische Medizin Mannheim, Universität Heidelberg, Germany.
Intensive Care Med ; 22(9): 909-15, 1996 Sep.
Article em En | MEDLINE | ID: mdl-8905425
ABSTRACT

OBJECTIVE:

To determine the efficiency of intravenous infusion of octreotide in the treatment of patients with severe pancreatitis and pulmonary failure.

DESIGN:

Prospective, case-control study.

SETTING:

Intensive care unit of a university hospital. PATIENTS Treatment group 39 patients with necrotizing pancreatitis were selected for the study. In all, pulmonary failure developed under conservative treatment and surgical intervention had been necessary because of local (abscess, necrosis) or systemic (systemic inflammatory response syndrome) complications. The outcome was prospectively followed up until death or discharge from the hospital. CONTROL GROUP 54 case-control matched patients with acute necrotizing pancreatitis and pulmonary failure, who had not been treated with octreotide. INTERVENTION Each patient in the treatment group received 100 micrograms intravenous octreotide three times daily for 10 days, in addition to the standard intensive care therapy.

RESULTS:

The groups (octreotide group, control group) were highly comparable with regard to age (mean age 54, 51 years), sex, severity of illness (Acute Physiology and Chronic Health Evaluation II score 27, 27), etiology of pancreatitis, and pretreatment at the time of admission to the intensive care unit. There was no difference in the development of renal, hepatic, gastrointestinal, hemostatic, neurologic, or local complications. But the frequency of the adult respiratory distress syndrome (18 vs 40%; p < 0.05) and circulatory shock (51 vs 87%; p < 0.05) was significantly lower in the treatment group. Furthermore, mortality was 26% (10 of 39 patients) in the octreotide group and 61% (33 of 54 patients) in the control group (p < 0.01).

CONCLUSION:

The results of our case-control study showed a beneficial effect of octreotide in patients with severe necrotizing pancreatitis and pulmonary failure. Based on these data, a prospective, double-blind, placebo-controlled study should be performed to evaluate these results.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Insuficiência Respiratória / Fármacos Gastrointestinais / Octreotida / Pancreatite Necrosante Aguda Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Intensive Care Med Ano de publicação: 1996 Tipo de documento: Article País de afiliação: Alemanha
Buscar no Google
Base de dados: MEDLINE Assunto principal: Insuficiência Respiratória / Fármacos Gastrointestinais / Octreotida / Pancreatite Necrosante Aguda Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Intensive Care Med Ano de publicação: 1996 Tipo de documento: Article País de afiliação: Alemanha